<SEC-DOCUMENT>0000886163-18-000071.txt : 20180518
<SEC-HEADER>0000886163-18-000071.hdr.sgml : 20180518
<ACCEPTANCE-DATETIME>20180518081023
ACCESSION NUMBER:		0000886163-18-000071
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20180518
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180518
DATE AS OF CHANGE:		20180518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		18845086

	BUSINESS ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ligand-form8xkre2018noteso.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3D4F182D463D5E73D60470E283DCB9AE"></a></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:173%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:173%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:173%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:173%;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;font-weight:bold;">______________</font></div><div style="line-height:173%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">FORM 8</font><font style="font-family:inherit;font-size:16pt;">&#8209;</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">K</font></div><div style="line-height:173%;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;font-weight:bold;">______________</font></div><div style="line-height:173%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:173%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:173%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:173%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Report (Date of earliest event reported): May 16, 2018</font></div><div style="line-height:173%;padding-bottom:9px;padding-top:16px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;<br></font><font style="font-family:inherit;font-size:8pt;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.53846153846155%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-33093</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">77-0160744</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Commission File Number)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3911 Sorrento Valley Boulevard, Suite 110</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">92121</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">San Diego, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Zip Code)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(858)&#160;550-7500</font></div><div style="line-height:173%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div><div style="line-height:173%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">N/A</font></div><div style="line-height:173%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:173%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:9pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:9pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:9pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:9pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:9pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:9pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table><div style="line-height:173%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:173%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). </font></div><div style="line-height:173%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Emerging growth company  &#9744; </font></div><div style="line-height:173%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:173%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01. Other Events. </font></div><div style="line-height:144%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 16, 2018, Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) issued a press release announcing its intention to offer $650.0 million aggregate principal amount of its convertible senior notes due 2023 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Offering&#8221;). On May 18, 2018, the Company issued a press release announcing the pricing of the Offering of $650 million aggregate principal amount of 0.75% convertible senior notes due 2023. Copies of the press releases are filed herewith as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.</font></div><div style="line-height:144%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01. Financial Statements and Exhibits. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exhibits</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit No.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="ligandannouncesproposedoff.htm"><font style="font-family:inherit;font-size:10pt;">99.1</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release dated May 16, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="projectlighthouse-pricingp.htm"><font style="font-family:inherit;font-size:10pt;">99.2</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release dated May 18, 2018</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:26px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-left:25px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.94017094017094%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:47%;"></td><td style="width:53%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LIGAND PHARMACEUTICALS INCORPORATED</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 18, 2018</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:50px;text-indent:-47px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:   </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Charles Berkman</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:50px;text-indent:-47px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:    Charles Berkman</font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:50px;text-indent:-47px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:    Senior Vice President, General Counsel and Secretary </font></div></td></tr></table></div></div><div style="line-height:173%;padding-top:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>projectlighthouse-pricingp.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s46C32CBB800746F3A45B70EAE297E811"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;"><img src="projectlighthousepric_image1.gif" alt="projectlighthousepric_image1.gif" style="height:30px;width:88px;"></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 99.2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.23076923076923%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Contacts:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand Pharmaceuticals Incorporated</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">LHA Investor Relations</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Todd Pettingill</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Bruce Voss</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;" name=""><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">investors@ligand.com</font></a></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">bvoss@lhai.com</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">858 550-7893</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">310 691-7100</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ligand Prices Offering of $650 Million of Convertible Senior Notes</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SAN DIEGO (May 18, 2018) - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)</font><font style="font-family:inherit;font-size:11pt;">&#32;announced today the pricing of $650 million aggregate principal amount of 0.75% convertible senior notes due 2023 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Ligand has granted the initial purchasers a 13-day option to purchase up to an additional $100 million aggregate principal amount of the notes, solely to cover overallotments, if any.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The notes will be unsecured senior obligations of Ligand. The notes will pay interest semi-annually at a rate of 0.75% per year. The notes will mature on May 15, 2023, unless earlier repurchased or converted in accordance with their terms. The conversion rate for the notes will initially be 4.0244 shares per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $248.48 per share of common stock, and is subject to adjustment under the terms of the notes. The initial conversion price of the notes represents a premium of approximately 30% to the $191.14 per share closing price of Ligand&#8217;s common stock on May 17, 2018. Prior to November 15, 2022, the notes will be convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, the notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, Ligand will satisfy its conversion obligation by paying or delivering, as applicable, shares of its common stock, cash or a combination of shares of its common stock and cash, at Ligand&#8217;s election.  However, Ligand will agree to settle all conversions in cash until such time as Ligand has a sufficient number of authorized but unissued shares of its common stock available to settle conversions of all then-outstanding notes in shares of common stock and has reserved such shares of common stock for such conversions. Holders of the notes will have the right to require Ligand to repurchase all or some of their notes for cash at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of certain corporate events, subject to certain conditions.. The sale of the notes is expected to close on May 22, 2018, subject to customary closing conditions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand intends to use approximately $43.6 million of the net proceeds from the offering of the notes to pay the cost of certain convertible note hedge transactions, taking into account the proceeds to Ligand of certain warrant transactions, each as described below, and intends to use approximately $49.7 million of the proceeds to repurchase approximately 260,000 shares of Ligand&#8217;s common stock from purchasers of the notes in privately negotiated transactions, which could increase (or reduce the size of any decrease in) the market price of Ligand&#8217;s common stock prior to, concurrently with, or shortly after the pricing of the notes, and </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">could result in a higher effective conversion price for the notes. Ligand expects to use the remainder of the net proceeds from the offering of the notes to acquire or invest in complementary businesses, companies, products and technologies and for working capital and other general corporate purposes, including, without limitation, research and development activities to maintain Ligand&#8217;s platform technologies and for development of Ligand&#8217;s product candidates being developed internally. Ligand has no current commitments or obligations with respect to any acquisitions or other strategic transactions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand has entered into convertible note hedge transactions with certain of the initial purchasers or their respective affiliates or other financial institutions (the &#8220;option counterparties&#8221;).  The convertible note hedge transactions are expected generally to reduce the potential dilution to Ligand&#8217;s common stock and/or offset any potential cash payments Ligand is required to make in excess of the principal amount upon conversion of the notes in the event that the market price of Ligand&#8217;s common stock is greater than the strike price of the convertible note hedge transactions. Ligand also expects to enter into warrant transactions with the option counterparties. The warrant transactions could separately have a dilutive effect if the market price of Ligand&#8217;s common stock exceeds the strike price of the warrant transactions.  To the extent that at the time such obligations are due Ligand has insufficient authorized shares available to satisfy its obligations under the warrants in Ligand&#8217;s common stock, Ligand would be required to satisfy those obligations in cash.  The strike price of the warrant transactions will initially be approximately $315.38 per share, which represents a premium of 65% over the last reported sale price of Ligand&#8217;s common stock on May 17, 2018, and is subject to certain adjustments under the terms of the warrant transactions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand has been advised by the option counterparties that, in connection with establishing their initial hedge position with respect to the convertible note hedge transactions and warrant transactions, the option counterparties and/or their respective affiliates expect to purchase shares of Ligand&#8217;s common stock and/or enter into various derivative transactions with respect to Ligand&#8217;s common stock concurrently with, or shortly after, the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Ligand&#8217;s common stock or the notes at that time. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand has also been advised by the option counterparties that the option counterparties or their respective affiliates are likely to modify their hedge positions by entering into or unwinding various derivative transactions with respect to Ligand&#8217;s common stock and/or purchasing or selling Ligand&#8217;s common stock or other of Ligand&#8217;s securities or instruments, including the notes in secondary market transactions following the pricing of the notes and prior to the maturity of the notes. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The option counterparties may choose to engage in, or to discontinue engaging in, any of these transactions with or without notice at any time, and their decisions will be in their sole discretion.  The effect, if any, of such activities of the option counterparties, including direction or magnitude, on the market price of Ligand&#8217;s common stock or the price of the notes will depend on a variety of factors, including market conditions, and cannot be ascertained at this time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The notes were offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Neither the notes nor the shares of common stock issuable upon conversion of the notes, if any, have been registered under the Securities Act or the securities laws of any other jurisdiction, and the notes and any such shares may not be offered or sold absent registration or an applicable exemption from such registration requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This press release does not constitute an offer to sell or the solicitation of an offer to buy any notes or common stock, nor shall there be any sale of notes or common stock in any state or jurisdiction in which such an offer, </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or any jurisdiction. </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Ligand Pharmaceuticals</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. We have a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand&#8217;s Captisol&#174; platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb&#174; is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly. </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; and &#8220;will,&#8221; and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding: the closing of the offering, the use of the net proceeds from the offering and potential share repurchases.  Actual events or results may differ from Ligand's expectations due to risks and uncertainties inherent in Ligand&#8217;s business, including, without limitation: risks and uncertainties associated with market conditions; and the satisfaction of closing conditions related to the proposed offering. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. Additional information concerning these and other risk factors affecting Ligand can be found Ligand's public periodic filings with the Securities and Exchange Commission available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"># # #</font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ligandannouncesproposedoff.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7ADEB561147CC2B3B84F71009542F98E"></a></div><div><div style="line-height:180%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:180%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:justify;"><img src="ligandannouncespropos_image1.gif" alt="ligandannouncespropos_image1.gif" style="height:50px;width:141px;"></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.23076923076923%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Contacts:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand Pharmaceuticals Incorporated</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">LHA Investor Relations</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Todd Pettingill</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Bruce Voss</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" name=""><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">investors@ligand.com</font></a></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">bvoss@lhai.com</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;858 550-7893</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">310 691-7100</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ligand Announces Proposed Offering of $650 Million of Convertible Senior Notes</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SAN DIEGO (May 16, 2018) &#8211; Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)</font><font style="font-family:inherit;font-size:11pt;">&#32;announced today that it intends to offer, subject to market conditions and other factors, $650 million aggregate principal amount of convertible senior notes due 2023 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).  In connection with the offering of the notes, Ligand expects to grant the initial purchasers a 13-day option to purchase up to an additional $100 million aggregate principal amount of the notes, solely to cover overallotments, if any.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand intends to use a portion of the net proceeds from the offering of the notes to pay the cost of certain convertible note hedge transactions, taking into account the proceeds to Ligand of certain warrant transactions, each as described below, and to repurchase up to $50 million of shares of Ligand&#8217;s common stock from purchasers of notes in privately negotiated transactions, which could increase the market price of Ligand&#8217;s common stock prior to, concurrently with, or shortly after the pricing of the notes, and could result in a higher effective conversion price for the notes. Ligand expects to use the remainder of the net proceeds from the offering of the notes to acquire or invest in complementary businesses, companies, products and technologies and for working capital and other general corporate purposes, including, without limitation, research and development activities to maintain Ligand&#8217;s platform technologies and for development of Ligand&#8217;s product candidates being developed internally. Ligand has no current commitments or obligations with respect to any acquisitions or other strategic transactions.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The initial conversion rate, interest rate and certain other terms of the notes will be determined by negotiations between Ligand and the initial purchasers.  Prior to November 15, 2022, the notes will be convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, the notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.  Upon conversion, Ligand will satisfy its conversion obligation by paying or delivering, as applicable, shares of its common stock, cash or a combination of shares of its common stock and cash, at Ligand&#8217;s election.  However, Ligand will agree to settle all conversions in cash until such time as Ligand has a sufficient number of authorized but unissued shares of its common stock available to settle conversions of all then-outstanding notes in shares of common stock and has reserved such shares of common stock for such conversions. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If the initial purchasers exercise their option to purchase additional notes, Ligand intends to use the resulting additional proceeds of the sale of the additional notes and any additional warrants sold to the option counterparties to pay the cost of entering into additional convertible note hedge transactions with the option counterparties and for other purposes as discussed above. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In connection with the pricing of the notes, Ligand expects to enter into convertible note hedge transactions with one or more financial institutions, which may include one or more of the initial purchasers or their respective affiliates (the &#8220;option counterparties&#8221;). The convertible note hedge transactions are expected </font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">generally to reduce the potential dilution to Ligand&#8217;s common stock and/or offset any potential cash payments Ligand is required to make in excess of the principal amount upon conversion of the notes in the event that the market price of Ligand&#8217;s common stock is greater than the strike price of the convertible note hedge transactions. Ligand also expects to enter into warrant transactions with the option counterparties. The warrant transactions could separately have a dilutive effect if the market price of Ligand&#8217;s common stock exceeds the strike price of the warrant transactions. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand has been advised by the option counterparties that, in connection with establishing their initial hedge position with respect to the convertible note hedge transactions and warrant transactions, the option counterparties and/or their respective affiliates expect to purchase shares of Ligand&#8217;s common stock and/or enter into various derivative transactions with respect to Ligand&#8217;s common stock concurrently with, or shortly after, the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Ligand&#8217;s common stock or the notes at that time.  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand has also been advised by the option counterparties that the option counterparties or their respective affiliates are likely to modify their hedge positions by entering into or unwinding various derivative transactions with respect to Ligand&#8217;s common stock and/or purchasing or selling Ligand&#8217;s common stock or other of Ligand&#8217;s securities or instruments, including the notes, in secondary market transactions following the pricing of the notes and prior to the maturity of the notes.  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The option counterparties may choose to engage in, or to discontinue engaging in, any of these transactions with or without notice at any time, and their decisions will be in their sole discretion.  The effect, if any, of such activities of the option counterparties, including direction or magnitude, on the market price of Ligand&#8217;s common stock or the price of the notes will depend on a variety of factors, including market conditions, and cannot be ascertained at this time.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and the shares of common stock issuable upon conversion of the notes, if any, have not been registered under the Securities Act or the securities laws of any other jurisdiction, and the notes and any such shares may not be offered or sold absent registration or an applicable exemption from such a registration requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This press release does not constitute an offer to sell or the solicitation of an offer to buy any notes or common stock, nor shall there be any sale of notes or common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or any jurisdiction.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Ligand Pharmaceuticals</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. We have a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand&#8217;s Captisol&#174; platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb&#174; is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; and &#8220;will,&#8221; and similar expressions, are intended to identify forward-looking statements. These </font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">forward-looking statements include, without limitation, statements regarding: the potential notes offering; use of any proceeds from the offering; the terms of the potential notes, share repurchases, and convertible notes hedge transactions and warrants; and whether the convertible notes hedge transactions and warrant transactions will become effective. Actual events or results may differ from Ligand's expectations due to risks and uncertainties inherent in Ligand&#8217;s business, including, without limitation: risks and uncertainties associated with market conditions; whether Ligand will offer the notes or be able to consummate the proposed offering at the anticipated size or on the anticipated terms, or at all; and the satisfaction of closing conditions related to the proposed offering. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. Additional information concerning these and other risk factors affecting Ligand can be found Ligand's public periodic filings with the Securities and Exchange Commission available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"># # #</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ligandannouncespropos_image1.gif
<TEXT>
begin 644 ligandannouncespropos_image1.gif
M1TE&.#EAQ@4+ O<           $! >1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P
M'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'G%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q=')R=7)R=7-S=G1T=W=V>7IZ?']_@(:&AXN+C)"0
MD)&1D9*2DI.3DY24E)65E9:6EI>7EYB8F)>:FY>;G9:<GY:=H):>H9>>H9>?
MHIB@HYJ@HYZBHZ"CI*6EI::FIJ>GIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O
MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+V]O;Z^
MOK^_O\# P,'!P<+"PL/#P\3$Q,7%Q<;&QL?'Q\C(R,G)R<K*RLO+R\S,S,W-
MS<[.SL_/S]#0T-'1T=+2TM/3T]34U-75U=;6UM?7U]C8V-G9V=K:VMO;V]S<
MW-W=W=[>WM_?W^'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOKZ^SL
M[.WM[>[N[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ^OO[
M^_S\_/W]_?[^_O_______R'Y! $     +     #&!0L"0 C^  $('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSYL(G.'/JW/G$IL^?0(,*'4JTJ-&C2),J7<JTJ=.G4)ORG$JUJM6J
M0Z]2U!JUJ]>O8,.*'4NVK-FS:-.J76OQJMNW<&U2/0AW;D&L;//JW<NWK]^_
M@ ,+'DP8:MW#B''2M$N7IT&\C1T#2$R9:^'+F#-KWLRYL^?/H,56'@TY9FF"
M4R/O1$BZ]>'0L&/+GDV[MNW;N,NZWMU3;NG4K.=:'<B;=^[CR),K7\Z\N?/8
MQ5L7C<Y8-77*S[-KW\Z]N_?OX$?^7J^\>?SH\.C3JU_/OKW[R^83EX\O_[W]
M^QX9Z-_/O[___P#RA]^ !!:(''VO:88@8@8VZ*!  48HX804,O#@A1AFR-:"
M<2G(88<:AHA>A2262**(**:HXE$?NC5?BY:M*.-R)M9H(X SYJCCCB?!.)R'
M/I[&XY"PW6CDC40FJ>22$ 59'7Q./LGDE)<=:66%5&:II9)12I99E\!M*:9@
M5Y8IX)AHIHDBF#J]R*9B:N;XII=-&4G8G#'&:1*8>BKTIE!XNOFGF'/>B>>A
M<'J'Z*(@;N@D3(PNV&"D'^Y9*)"7:AEH6I1VBMV7GH:*(%A\@B1JI\V=&FI&
MFX+::I;^KT:EZJS%F47KK:4JE>M$N/;:IF>^!OLK0[$6ABBAF>HJ[++&+<7L
MLU%.UV5#T%:;4V#69CNL0,4:VNV2WP)UZTNX2FMM2=I>^].NDZ7K[FIHO2LO
MI8*RB>R@0:%J&+WK)DL6K37-F^!BY7X5K+@"OU4ONU.&2^ZQ:T$<\'6@Z6M:
MPKW)*JI4IXJ6\,+3;NDP2R-'[*],C2ZWZ,75ZF4Q4:OZ=2ZF^,)ZLDLW8UMS
MGZ@=^G"O4*Z<;Z3  DVSO2+GK)+2@^W,,W$EB]1Q:$)/7'5M&Q_-,)-1H[NU
MJR$_?1?3)#&:F\0L^^S<U4&3/637XB%=]-=/P^V1W53C;2K^VMKI[:C?*@)^
MM]P@PRAV<$[WZ#9M@F_$]W:-QZNVIHM[37C;81\^=N*6<H[;Y$N#KFCE?#W.
M->F6T]U7Y#9[7C;JT,'NN.BCNPZ8Z>#*_KKN!M,.-L:>ML1ZX3Z2/#S6O*N%
M.Y?)[[[\OF;_#;R\PC??V?$1/=^W]6=I_S;WG;\\=-:D3F^^D(K;;AOV3?K>
M'?L>P^^@_*F?[VY7]N>?,DKT-PV^1-Y[3O^\$L =#7!P^IL9].[',?6%Y("W
M^U_VW,<=""[0@0:4( (3N*SRJ4IF&IP@!F=C0<2%$#8E=$H!=91"A]B+@Y_2
M#;\PT\+'G-!;ETM?#8UUP][MD#W^/[1.BR["P BNT(@YU*'J;A-$;AWQ0#TD
M( 63U$0G!DES/:OB4ZJH1<F-<&]39$X781;&[WV1(]'"HA6CZ,4DAF^)ZV.C
M"]F6JC*"<(S?:6+F#F='K3W*>&=$H1P?0K3CQ.QW;F1>(#6"1_<\46=]_$@C
M_S7(]A6R8N/R8QHIMTA&?I!*=/1?\ "9R,]5$H#B^TO+-/E'3I;RC3 TFA1#
MJ3Q?5:^3GYFD$&<H0^JQ\HI)PR488WD^J_$2?]JZY2OC*$S^91(I'"0>,8N9
M$ETF9)JQ7(DLTT9-;9ZR=-^<73+1:+0]\A";Q'1F,W^&SOS!LIV%W&3HUBG-
M(:H0GH?^W&6E?HG/CRG1G#[IIT S)K6!%N^:K9SG,I%'3]\85%*\DB?F'HHQ
M=2[4HI&,'[,P2M&!B?"@WFPH(B7:RXXJK", G:A)LZ50.!8THR.E937Q^5*0
MMC2E9PMG5M 94F"JL4#-FLDC22C3\<W***Y1UFX&5"N5 >R"#/JI5/])TMJ)
M=*I8S:I6M[JFJS)1IUP-JUC'2M;D@)4SUBRK6M?*UK::S*L,A:M;YTK7NMKU
MK1>M8UKORM>^^O6O/=VK!XL*V,(:]K"(5>HH<SFUQ#KVL9"-+,)6J;%G2?:R
MF,VL9I6Y4FQN]K.@#:UH:]I97X[VM*A-K6K%6=K%KO:UL(W^K6PEV=JESO:V
MN,VM;OLUSMWZ]K? #:YPATO<%=F41?$IKG*7R]S#"A9]1)12<Z=+W>I*59?0
M#=/FX+7=;<W1H]8-KWC':Q_L:K>[=;E)/LG+WO:ZEZAR;8MTSPLU.JWQ5T-]
MKW[WRU].G960/]I*@.O[W_X:^, (QEF!,4*:C\8WP1".L(1O6E51+GC"&,ZP
MAHEU83(*=L.S,=.50$QB*#X8F1\N<6=$S.+]J/C%L3MQ93L,X]"T^,;ZJ;&.
MT4IC0,%TQ^'!,8Z!3&0<NG1U/RYR=X3<8B4[694]-JJ,GUP;)H^8REAV690G
MN^4L9\;*$O*RF/>28I0E.8,<DHW^P#0437XF=:<=1/-&.8M32'9Y>U.6<FF_
M6ML8CN7(K*(I>@9*VSS?L\Q.-32=^UP?,C.ZSDB%M"4?S5WX4IJ^U+JS0S4M
M0$ZC\M(0A2JH+VFNA&9ZU'ZV,*K)@U!%,R6_*4*T/E=M..32^JE<]JD-;TT=
M+?.:/NURM;/.'&M/HS=Z'G9M0,D'35MN^HJ??""T*#GG^L&SGK5V): #*^N*
MD%JHV4;BM]DYO:3@^M#15BSPL&U/;4N:V^^F]IVEPV=8H_1=ME)VJ8^9[W2Q
M>Y_NKC IM^U?85^(L-;>)CB1K6=[R]O9,14X%:-L;#/G]5X&/[:^57IQCG9[
MV>GFN,3^B=3(C ^;X!A'.3G'G3=B#_/CYF:YJCLN(SR:_-4T#[BI9UIQG)?<
MX8*\>:1AGE.A$WCD,]\Y'PM,]&9W&.'*:3J%X\W"'AM]Z"H/9LX]>?62;IWK
M/7\XU1TM=69^?8-CEU[6M;YV!H<=W6V/;ME1?/8V=MVJ<4=[VKV>=S?O>>![
M;WG=O>WR>O>=[X?'T',+K^Z[6_S7O08\TN.:^$D[?N&#[_?;39SYN#&\@3+W
M(>0K[^# 8S+C0#<[Z<.2^@S!7.$>9_:,1\]OJBK=D&=M/>,VOVC3%_OR *9]
MJ.$N_)#'7M=1SSWC5>_[@O.^Z)TG;?$I1G?8:W3UP8\^#97^O_S= Q_DSS?E
M]X,]_: .MO9(OOG<L8[]4Z]?U+<7C.X/;G5(3S,OH3=R\^6N?9$?]_B3EVC]
MQWK=IW@7%H"!-GYP%GZ/UW[NYX!V!H$<5H"")X'PAX!RPG3QUR?SIW;[)U\*
M.$L#6'HA*'88Z&L,R'PGR%KAICD4B((6V&HCF'0;:'LQB'D=2(#OIV;<]X%F
M5(+[YH,"!H07^'^]1X0+N%[GE(*4)X2?EH.N]X*:!X7?-8/RUV4;IW_GYG_(
MUS +)E#@\7EW9'PV:(2XIX"RYX&6Y7< USI62(+EUX8^EG^B)RQ':(;0=X,@
MV%BSMV9L&(==6(8M"&Z *(8\IX3^R69:4Q>(9_B&>O=,W)1.?UB(-?B(E?AL
ME%A#+ 5VUR9YE^A]CBA]F=A@&I=FDSB*@RB*GTB(J)B%]]:*0K*"+.B$VX>$
M50B+E:9>JTAVN*B)GH9^A#=Z[T1[V9>*P\B(>4B+X$>,;K>+O-B+>GA?RCB$
M4OAGD B !C6+<HB-[2: T6A,)N4\>'B*T'@>=VB*\#:-5VB(D3@OZ9A<D/*-
MSXB,Z^B'K+B-8T:.XQ$>5,A;YIB/U_5F  E8.RB"\CB0")F0=1.*0<>0"OF0
M$*DFMHA7#AF1%GF1N3.1W5.0&-F1'IE'U<AC(?F1)%F2/PAUC 6,)KF2+,DS
M$)=^6]C^DC(YDR[83GN80#29DSJY5>7HBCOYDT"I53V)CT%9E$9I5T,Y8$>Y
ME$RI6GW6E% 9E5(YE51I>/]HD%=9E5JYE7=5D<V8)Z68BUPYEF0IE+\(77"H
M+F6YEFPI-GMU&JQ6BFTYEW0Y)M8D7>2GED<GEFA9EW[YEX&S97B9EXFB<2;D
M78"9F(H9A9<WF'%YF'I)F*.RF)19F2GIE1,HEGL)7EFDDI;YF:!)D>IXDY&Y
MF9!9F)O9$_T8FJS9FOYXD+IH7Y(I@]N"%ZOIFKB9FPJ&ADH9C.=UF[H9G,(I
MCJ.Y<KUYFK(IC; YG,S9G$^XG-1H?K2)F<Y9G=:9F= 9A-G^>9W<:9T<J8JR
MV)WB.9X1I9&>&)[DF9[J.9WHZ7SFN9X*P6+P"9'?*6WU69U@%F;SF67W66A,
MR)WY62/[Z63]:8GM.: B$:!(@J! 5J"O^)_.J:!VPJ ZYJ#&^9[7*:%'0J$U
M9J':6)P<&A$:.J$A6F(>RHG46:(&,:(DJJ(:=J()"*',R:(VXJ(D!J-?B:'6
M2:,":J,;AJ/\IZ,[RJ,GXJ,O*J/$N9TN2J048J0_BJ2>!Z4SRJ0XXJ1/*J2"
M.(Y66A)4FF-;"F) 2II*^I!9^14!>IFIAEM1A5B-!GICVG @.B/[HU<O676]
M)7Y@27R>>9(^N8A:"F5ANH3T&('^YG,?V2ANZ-B FQ@B]IBE1%F/6&II;TIN
MA"9&MU9+!QJ=^O,>/&6?*>IT4GIZGTJICU:!E&B-F8J=8 @Y*W6A<5J$@\JG
MJ9J$S(BH24E0>MJ-*-I:9C5J8NJ,^#>2!.*@O2B:MWJ<M@:LN_9K/%BKM_BJ
M6R2L3!6JQXJK?5BM;<I^?SIKPOAOS!J;D_J:HSIH,HJMF :JYFI;B;BMRIF)
M- B+W&J,D#JN_,B$Z9JGM'JOZ@JGC]JNQ8J#U9J:L3J&D=JL]%J>=>JJ!;.N
M^AH=_)JH IN4:MBP!9NDT%I>FW=4F-BG[<B']W@PRPA2":NJBXJJ=XJPX:B/
MYI%R%QO^I"@9LB_[CN$:HV1(JC"TFR,;K2!KLVT6<<H:F$"XIS''CO'XL]=*
MM.>Y;G-8LR>GL=I9;BJ[CVS7LL\9JGX2L\?85#[K>(6:JTC[M'28K/ZTM>QJ
MIP>+G+,ZM/.FM0T)G,]ZLEB)M02#B.<'MUI(M>V15M*JK6FKL/BJ@F?K;Y@:
MMN#XM8@79V0KKQ,'?('ZMD:;.B"YMR2;L^[IMC0KMX>[L+5HM7-SMA&KN #[
MN!GY='8XKX@FM#"IN5Q8MAG(M14+GJ KD9)[M==XMS/;F98;MW1KNG@+1!3G
MN4O;N_1W@$R[NJS+C:(+J+M+J+?;:7?WN@EWO%,KO)\+O3+^F[P&2KTF.+MN
M"KP55'_-"[,#FR9:A+K>.GQ%R[TPV+@HZ[VLVG76&[VQ*[M"E[N#"[R&FXS:
MR[?[6Z_PZ[[Y*KW3.[XOU[^92\"PV[?7P[G9B\!R2F/Q:['S2[^CRK[(VZ^.
MJJMX!L ;:\"1&[@<G&O8.[K+:<$7C+[7*\!6J< ZR, BZ;D1[*DLS"-<Y,(?
M.\.6%\-@J\+W&\)K [X>S+ .;)<:J,,WC,..B\0O'+Y'K,33ZKI,K*@C3,+:
M:\(9#+$GC,7?:\0?ZL3X,4E6#*Y!/"E%[,/55\7J*ZAC+,)1[(UK',9HR\.6
MNJHIC,& .\2[NL;KZ\4Z:\-1Z[#^<\O%.:S'35M\YZC!G >;]FN\6ORN4SR\
M'+S(3<S'A=R3AVS'34C)RVK&E:O)/N?'B=O('4O(!0S*DYNNERS*>'J0DJS&
MGES);9Q\)6B^_&O*N$NQ@RG!<KS J)?&C(S"MOO(#R)K'"NN^=N]N'Q2=:S*
M*RS,2>S,;4O*A1O+O3J13AO(:0BKR:S,?CK!DBJ\K1S,WCR/U)S(TDR[.^NW
MM8O,VTR*RPS,C<C*ONS*T%R'G.S&KZS.^GK&[2R=60QL="K/<"S%]:R[^;P>
M1-?/I0G+FXK-:"S(H[S+FEK.VXO'QGK. 8W1MXS+_)S.!BW1ODG1#&W1+GO/
M4ZC1$4W^TET5M/W\T<5<MP?MKR#]QVS[SY/IOR;-LP4]K)S6SBW\TANI?K:L
MT^.LSRK=S$<=U$,MSHA,U$-YP! =T@^=T^R<U!,MTC"]TT<;T^D!QNQ2J78W
MSVI;PDN=RO LOUI]OO 8RI@L9TJZ;=VTQU'=Q3/=OES=R6G-GECMTDW-NW>-
MT]O)PM;'O'N=OF0]US@+G9B+U'5MLHCMR$7]H)&MR\C*V'G]TU-=V&*[OXM]
MQXU]?50=SYG=UQPHUEO]V8-\V:&KVG',VGZ-VEG]UV%8QJ1=VF7MGX<=VB,-
MVVDIVQ/KVHVGV:"HR,!M@ -=TL4MTY,MJH%]S,-]VW:-TK+^_*F^S=/0W<"U
MG<#9G<G)'9;2O=NZ_<[,+*O%'=[O^]BEW-W'':5C2LLT/=X$:]Z>O=S(S=N_
M=]UT;=^GK-^VVMV;',[:W-EX7=WO\U\ CK'KW=M<G> RK,>IQ-8"'M;"_<TQ
M#=0T;-KH&N&_:M7OO:\$S>#_K;KT3.!;7,'5]L 8'KP/GK7TW;FWF\W!2EF;
MB]Z$S>%2#:^K/>'Y[=Y&O=W/3>+>;<'XUN'^?#K_J]":6<LZ?M77?(A+KN)
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M%>90?^?S81!K@D)S]5"($UF3)SR!EL;Q$%[N\E&JHB05(J[%@AM<5J2JE$4
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+W+_ZX"=^I@@( #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>projectlighthousepric_image1.gif
<TEXT>
begin 644 projectlighthousepric_image1.gif
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M6G38?"I^V"-X-PHG'VP3%MF4=#(B9.2$P.WH$FL\EJA;DAUR%F5D5#ZY))-
M9IEACE<&6=F6C"DII8$_(@CFBF2J9N:9)L9YFI="IBGGG7CFJ2=Q=OJTYIZ
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M#K>"<)B%3KAJ;UB)CBB#D)@WT!9MF:B$X:=LSU6(B%ANE">$Z^>"?':#J1:
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4@6)9ELNXD6:9EMRHB6H)*0$! #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
